HEALTH

Eli Lilly Sells Rights for 2 Antibiotics to Dura: Indianapolis-based Eli Lilly & Co. said the move was an effort to reduce some of its marketing expenses by selling the exclusive rights to the drugs for at least $100 million. Dura Pharmaceuticals Inc. will begin promoting Keftab, used to combat pneumonia and strep infections, to doctors once federal regulators approve the deal, and will launch Ceclor CD, a stronger version of the bronchitis drug Ceclor, in time for the upcoming cold and flu season. Lilly would continue to manufacture the drugs and Dura would pay Lilly undisclosed amounts beyond the $100-million up-front payment. Dura is a San Diego-based drug company specializing in allergy drugs.